Avisi Technologies Presents Positive Six-Month Clinical Data for VisiPlate® Aqueous Shunt at the American Glaucoma Society
REDWOOD CITY, Calif., April 2, 2025 /PRNewswire/ — Avisi Technologies, a clinical-stage ophthalmic device company, today announced encouraging six‐month interim results from the VITA trial evaluating its VisiPlate® device, an ultrathin, multichannel aqueous shunt in study subjects diagnosed with open-angle glaucoma. Data were presented by Eydie Miller-Ellis, MD, as a Top Paper at the American Glaucoma Society Annual Meeting in Washington, D.C.
